Sponsor

Janssen Pharmaceutica

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Janssen Pharmaceutica appears in 18 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials18
Recruiting shown1
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

18 shown
A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino PatientsNCT01726348 · lead sponsor · 2014-01-01
WITHDRAWN
Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate CancerNCT01692483 · lead sponsor · 2013-07-01
WITHDRAWN
A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing SpondylitisNCT01692457 · lead sponsor · 2013-07-01
WITHDRAWN
A Study on the Safety and Effectiveness of Rilpivirine Hydrochloride (Edurant) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I InfectionNCT01692470 · lead sponsor · 2013-06-01
WITHDRAWN
A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With SchizophreniaNCT01606228 · lead sponsor · 2007-12-01
COMPLETED
Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With SchizophreniaNCT01662648 · lead sponsor · 2007-06-01
COMPLETED
Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.NCT00825929 · collaborator · 2009-02-01
RECRUITING
MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's DiseaseNCT04121208 · collaborator · 2021-04-07
TERMINATED
Inflammation and Co-Infections in D²EFTNCT04183738 · collaborator · 2021-02-01
WITHDRAWN
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate CancerNCT04592237 · collaborator · 2020-12-29
ACTIVE_NOT_RECRUITING
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After ProstatectomyNCT04181203 · collaborator · 2020-01-09
ACTIVE_NOT_RECRUITING
Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RPNCT03899077 · collaborator · 2019-04-05
UNKNOWN
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)NCT03141671 · collaborator · 2017-11-24
UNKNOWN
Dolutegravir and Darunavir Evaluation in Adults Failing TherapyNCT03017872 · collaborator · 2017-11-23
UNKNOWN
Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDSNCT02155101 · collaborator · 2014-05-01
COMPLETED
Alzheimer's Disease Biomarkers in Cerebrospinal Fluid in Insulin-resistant MenNCT02010476 · collaborator · 2013-11-01
COMPLETED
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)NCT00928187 · collaborator · 2009-11-01
COMPLETED
Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant DepressionNCT00179244 · collaborator · 2004-07-01
COMPLETED

Drugs studied in this sponsor's trials

15 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Janssen Pharmaceutica as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
apalutamide3
darunavir3
dolutegravir2
prednisone2
ritonavir2
abiraterone1
abiraterone acetate1
bicalutamide1
apalutamide RxCUI 1999574 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 3 trials darunavir RxCUI 460132 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 3 trials dolutegravir RxCUI 1433868 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials prednisone RxCUI 8640 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials ritonavir RxCUI 85762 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials abiraterone RxCUI 1100072 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial abiraterone acetate RxCUI 1100071 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial bicalutamide RxCUI 83008 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial cabazitaxel RxCUI 996051 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial carboplatin RxCUI 40048 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial degarelix acetate RxCUI 835863 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial gonadorelin RxCUI 6384 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial goserelin 10.8 MG Drug Implant RxCUI 314008 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial niraparib RxCUI 1918231 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial triptorelin pamoate RxCUI 338529 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

collaborator12
lead sponsor6
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.